Stock TPST TEMPEST THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Tempest Therapeutics, Inc.

Equities

TPST

US87978U1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
2.1 USD +3.96% Intraday chart for Tempest Therapeutics, Inc. -1.87% -52.27%
Jul. 01 Tempest Therapeutics, Inc.(NasdaqCM:TPST) added to Russell Microcap Growth Index CI
Jul. 01 Tempest Therapeutics, Inc.(NasdaqCM:TPST) added to Russell 3000E Index CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
GL
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat in First-Line Hepatocellular Carcinoma
AQ
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
GL
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
BU
Tempest Therapeutics : Corporate Presentation - June 2024
PU
Tempest to Participate in Upcoming Investor Conferences
GL
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
AQ
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
GL
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
GL
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
AQ
Tempest Therapeutics : Corporate Presentation - April 2024
PU
Tempest Therapeutics : Corporate Presentation - March 2024
PU
Tempest Reports Year End 2023 Financial Results and Provides Business Update
AQ
Tempest Reports Year End 2023 Financial Results and Provides Business Update
GL
Tempest Therapeutics : Reports Year End 2023 Financial Results and Provides Business Update - Form 8-K
PU
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
BU
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TPST Stock
  4. News Tempest Therapeutics, Inc.
  5. Press Releases